Control points cluster around instrument qualification, method validation, and regulatory compliance, where manufacturers and system integrators influence adoption speed. Dependency risks arise from limited supply of high‑purity reagents, proprietary software ecosystems, and evolving GLP/ISO standards that can delay lab commissioning. Switching costs are elevated because assay re‑qualification, data migration, and equipment re‑training require significant investment, encouraging long‑term partnerships. Interoperability between LIMS, analytical hardware, and cloud‑based analytics is therefore a critical negotiation lever. While North America and Europe exhibit mature, standards‑driven networks, emerging markets rely more heavily on local distributors and flexible financing arrangements, shaping regional value‑capture dynamics. Financing and leasing partners further shape adoption by mitigating capital expenditures, especially in cost‑sensitive regions.